Introduction {#Sec1}
============

Steroids synthesized in the central nervous system can influence neurophysiologic processes, mood, and behavior. The term "neurosteroid" refers to endogenous steroids synthesized from cholesterol in the central and peripheral nervous system, independent of steroidogenic activity of the endocrine glands (Baulieu [@CR3]). The term "neuroactive steroid" (NAS) subsequently was used to refer to endogenous or exogenous steroids that have a direct nongenomic effect on neuron excitability (Paul and Purdy [@CR37]; Lambert et al. [@CR23]; Rupprecht [@CR46]; Stoffel-Wagner [@CR52]; Pisu and Serra [@CR40]). NASs bind to a distinct site on the GABA~A~ receptor and influence the frequency and duration of the chloride channel openings, thus modulating GABAergic transmission and GABA mediated behaviors (Paul and Purdy [@CR37]; Lambert et al. [@CR23]; Majewska [@CR25]; Concas et al. [@CR11]). Potent neuroactive steroid modulators of the GABA~A~ receptor function include allopregnanolone (ALLO), allotetrahydrodeoxycorticosterone (THDOC), and dehydroepiandrosterone (DHEA) (Rupprecht [@CR46]; Majewska [@CR25]). THDOC and ALLO act as positive allosteric agonists of the GABA~A~ receptor while DHEA in the sulfated form can display antagonistic properties at the GABA~A~ receptor (Majewska [@CR25]).

Several authors have suggested that the disequilibrium of NASs may be a factor in the pathogenesis of major depression or a risk factor for the development of affective symptoms (Rupprecht [@CR46]; Pisu and Serra [@CR40]; Bernardi et al. [@CR5]; Strous et al. [@CR55]). In animal models of depression, lower levels of allopregnanolone have been found in the frontal cortex and amygdala (Uzunova et al. [@CR59]). Exogenous administration of ALLO and DHEA in preclinical and clinical models demonstrated antidepressant effects (Uzunova et al. [@CR59]; Khisti and Chopde [@CR21]; Khisti et al. [@CR22]; Matsumoto et al. [@CR26]; Pinna et al. [@CR39]; Serra et al. [@CR50]; Wolkowitz et al. [@CR65]). NAS have also been implicated in the positive effect of selective serotonin reuptake inhibitors (SSRIs). SSRIs were shown to catalyze the rate limiting step in the synthesis of ALLO (Mellon and Griffen [@CR27]). In the olfactory bulbectomized rodent model of depression, treatment with different antidepressant medications that affect serotonin reversed the bulbectomy-induced decline of ALLO (Uzunova et al. [@CR60]; Uzunova et al. [@CR61]).

Menopause represents a time of vulnerability for onset of depressive disorders (Rubinow et al. [@CR45]; Joffe and Cohen [@CR20]; Cohen et al. [@CR10]); between 22 and 33% of menopausal women report mood deterioration and depression (Zweifel and Obrien [@CR68]). Significant changes in hormonal concentrations occur at the time of menopause. Estrogen concentrations decline precipitously and the ensuing hypoestrogenic state has been linked with substantial alterations in physical and psychological functioning. Estrogen deficiency has been proposed to increase the susceptibility for depression (Birkhauser [@CR8]). In a large meta-analysis, estrogen therapy appeared to be effective in reducing symptoms of depression in menopausal women (Zweifel and Obrien [@CR68]). Exogenous estrogen has been a useful monotherapy in treating depression during the menopausal transition (Schmidt et al. [@CR48]; Soares et al. [@CR51]; Rasgon et al. [@CR42]; Cohen et al. [@CR9]), as well as an augmentation strategy to antidepressant medication (Westlund and Parry [@CR63]; Liu et al. [@CR24]; Morgan et al. [@CR30]). Studies in postmenopausal depression however, have not been as consistent (Cohen et al. [@CR10]; Morrison et al. [@CR33]; Rasgon et al. [@CR43]).

Estrogen has been proposed to alleviate depression via influencing serotonin and norepinepherine (Bethea et al. [@CR7]). However, it has also been proposed that the deterioration in mood in menopausal women may be related to changes in levels of neuroactive steroids (Genazzani et al. [@CR17]). Similar to estrogen, neuroactive steroids also decline post menopausally (Bernardi et al. [@CR4]; Barbaccia et al. [@CR1]; Genazzani et al. [@CR16]), and could conceivably contribute to menopausal depression. Exposures to a variety of menopausal hormone treatments have been shown to increase ALLO and decrease DHEA in non-depressed postmenopausal women (Bernardi et al. [@CR4]; Pluchino et al. [@CR41]). NAS have not been evaluated in depressed menopausal women given estrogen. Additionally, most studies evaluating NAS and mood in reproductive-aged women were not controlled or did not differentiate the effects of estrogen from those of progesterone, the immediate steroid precursor of the NAS (Bernardi et al. [@CR4]; Pluchino et al. [@CR41]).

As part of a previously published study on estrogen acceleration of SSRIs in postmenopausal depression (Rasgon et al. [@CR43]), we elected to determine if postmenopausal women with and without major depression exhibit different peripheral levels of the NAS ALLO, THDOC, DHEA, and NAS precursor, PROG. We also investigated whether the administration of a selective serotonin re-uptake inhibitor (SSRI), sertraline with or without the addition of estrogen influenced NAS concentration in postmenopausal women with major depression. Finally, as prior reports of the effect of hormone replacement with estrogen on NAS were uncontrolled and often included progestins, we assessed in a placebo controlled fashion, whether the administration of estradiol to non-depressed menopausal women affected NAS concentrations. We hypothesized that NAS would be lower in the depressed women and that both the administration of the E2 patch and the SSRI would increase NAS concentrations.

Methods {#Sec2}
=======

Postmenopausal women with unipolar depression and controls were recruited from the UCLA Mood Disorders Program, newspaper advertisements, flyers, and other community venues as previously described (Rasgon et al. [@CR43]). Inclusion criteria required cessation of menses for a minimum of 12 months, plasma levels of follicle stimulating hormone (FSH) greater than 40 mIU/ml and estradiol (E2) levels less than 20 pg/ml. Subjects were required to have a normal mammogram, pelvic examination, and physical examination within 6 months of enrollment in the study. Exclusion criteria included previous estrogen replacement, prior antidepressant exposure, psychiatric disorders other than depressive disorder, current use of hormonal medications, current use of tobacco, significant vasomotor symptoms and medical illness in which estrogen use may be contraindicated (cardiac disease, clotting disorders, breast cancer, abnormal uterine bleeding, renal disease, or liver disease). All subjects signed the informed consent form approved by the UCLA Office for Protection of Research Subjects prior to study enrollment. All experimental procedures were conducted in accordance with the Declaration of Helsinki. A Structured Clinical Interview for DSM IV was administered to determine whether subjects met inclusion criteria for major depressive disorder (MDD), and to rule out other Axis I diagnoses.

Both depressed and control subjects were randomized to estrogen or placebo transdermal patches from the onset of the study in a double blind manner. Patches were applied twice weekly to ensure maintenance of adequate estradiol levels, with the estrogen patch release rate of .1 mg estradiol/day. All depressed subjects received sertraline concurrently with the estrogen or the placebo. The initial dose of sertraline was 50 mg per day for the first week, increased to 100 mg/day for the remainder of the study. The Hamilton Rating Scale for Depression (Ham-D) was conducted at the initial visit and weekly thereafter for ten weeks. Individual items from the HAM-D for psychological anxiety, somatic anxiety, and agitation were used to create an anxiety scale. Baseline phlebotomy was conducted prior to interventions and at the end of ten weeks of treatment to measure serum ALLO, THDOC, DHEA, and PROG as part of the larger study addressing differential treatment response and cognition.

Steroid assay {#Sec3}
-------------

Blood samples were collected in tubes containing clot-activating factor and were immediately centrifuged. The serum samples were stored at -80°C until assayed. For the neurosteroid assay, 1 ml of serum was diluted with 2 ml of water and then extracted three times with 3 ml of ethyl acetate. The recovery (90%) of steroids through the extraction procedure was monitored by adding a trace amount of \[^3^H\] cortisol (6,000-- 8,000 cpm, 52 Ci/mmol). The neurosteroids were quantified by radioimmunoassay as previously described (Follesa et al. [@CR15]) with specific antibodies to DHEA and PROG (ICN, Milan, Italy,). Antibodies to ALLO and THDOC were generated in rabbits and sheep, respectively, and were provided by Dr. R.H. Purdy (Scripps Research Institute, La Jolla, Calif., USA). The limit of detection of radioimmunoassay, expressed as minimal amount of steroids distinguishable from the zero sample was 0.01 ng. Intra- and inter-assay coefficient of variations ranged between 5 and 7% and between 9 and 11%, respectively. Estradiol was assayed by commercial kit (ICN Pharmaceuticals, Costa Mesa, Calif., USA).

Data analysis {#Sec4}
-------------

Independent t-tests were used to assess group differences in demographic and baseline clinical variables. Between and within group changes in NAS levels from baseline to end of treatment were assessed with repeated measures analyses of variance. Multivariate analysis of variance (MANOVA) was used to analyze differences in NAS profiles between depressed subjects and controls. MANOVA was also used to assess group differences in NASs in depressed subjects on sertraline plus estrogen versus sertraline plus placebo. The relationship between mood and NAS concentrations was evaluated with bivariate correlation analyses.

Results {#Sec5}
=======

**Demographics** Twenty eight postmenopausal subjects were enrolled in the study. Sixteen met criteria for major depressive disorder and 12 were asymptomatic controls. Participants were randomized to receive either estrogen or placebo with 8 depressed and 6 controls receiving estrogen, and 8 depressed and 6 control subjects receiving placebo. Means and standard deviations of age, years since menopause, age at the time of menopause, parity, education, body mass index (BMI), and baseline Ham-D are contained in Table [1](#Tab1){ref-type="table"}. No significant differences were seen between depressed subjects and control subjects in the demographic characteristics with the exception of education. Depressed subjects had significantly less education than controls (*t* = 3.06, *p* \< .05). BMI was higher in the depressed subjects compared with controls however the difference did not reach significance (*p* = .052). By definition, depressed subjects had significantly higher Ham-D scores than control subjects at baseline. Table 1Demographic variablesDepressed (*n* = 16)Control (*n* = 12)Total (*n* = 28)MeanSDMeanSDMeanSDAge54.504.9957.915.5955.895.42Education (years)^a^14.911.5417.182.3215.832.18Menopause (years)5.334.409.066.686.735.54Age at menopause47.335.7549.392.8948.104.91Parity1.401.351.551.211.461.27BMI29.386.2325.452.7827.705.35Baseline Ham-D^b^21.753.494.081.7313.758.93^a^Depressed subjects had significantly less education than controls (t(25) = 3.06, *p* \< .05)^b^Depressed subjects had significantly higher Ham-D scores than controls (t(26) = 17.28, *p* \< .001)

**Baseline differences in NAS between depressed and normal control subjects** Table [2](#Tab2){ref-type="table"} contains descriptive statistics of baseline concentrations of ALLO, THDOC, DHEA, and PROG for depressed and control subject. Prior to treatment, MANOVA revealed a significant omnibus test (F (4, 23)^)^ = 4.99, *p* = .005). Univariate follow-up tests indicated that ALLO and DHEA were significantly lower in the depressed subjects compared to the healthy postmenopausal women (t(26) = 2.42, *p* = .023 and t(26) = 2.48,*p* = .020 respectively). Table 2Baseline neuroactive steroid concentrations (ng/ml) in depressed menopausal women and healthy menopausal controlsDepressed (mean ± sd) n = 16Controls (mean ± sd) n = 12t-statisticp-value**PROG**1.07 ± 0.270.96 ± 0 .20-1.19.243**ALLO**4.34 ± 1.146.00 ± 2.34-2.42.023^a^**THDOC**1.69 ± 0.874.73 ± 6.861.76.089**DHEA**0.81 ± 0.491.57 ± 1.092.48.020^aa^Statistically significant difference (*p* \< .05) between depressed subjects and controls in ALLO and DHEA at baseline

**Change in NASs from baseline to end of treatment** Table [3](#Tab3){ref-type="table"} contains descriptive statistics for NAS before and after estrogen or placebo treatment in depressed menopausal women on SSRIs and healthy menopausal controls. There were no significant differences between or within groups in any of the NASs, nor were there significant interactions. Table 3Neuroactive steroid concentrations (ng/ml) before and after estrogen or placebo treatment in depressed menopausal women on SSRIs and healthy menopausal controlsDepressedControlBaselineEnd of treatmentBaselineEnd of treatment**PROG*Placebo***1.07 ± 0.371.06 ± 0.131.03 ± 0.161.07 ± 0.26***Estrogen***1.07 ± 0.141.01 ± 0.230.89 ± 0.230.98 ± 0.26**ALLO*Placebo***4.18 ± 1.173.99 ± 0.447.39 ± 2.846.10 ± 1.66***Estrogen***4.51 ± 1.164.30 ± 0 .964.62 ± 0.548.38 ± 6.98**THDOC*Placebo***1.64 ± 1.001.84 ± 0.908.19 ± 8.588.98 ± 10.11***Estrogen***1.75 ± 0.792.00 ± 0.961.28 ± 1.121.23 ± 1.01**DHEA*Placebo***1.03 ± 0.490.87 ± 0.581.32 ± 0.901.19 ± 0.48***Estrogen***0.59 ± 0.410.88 ± 0.801.81 ± 1.291.93 ± 1.04No significant changes in NAS after estrogen or placebo treatment in depressed or healthy menopausal women

**Effect of SSRI plus estrogen or placebo on NAS** In depressed subjects, NAS and PROG did not change significantly after SSRI treatment plus estrogen or SSRI treatment plus placebo.As reported previously, all of the depressed women responded to treatment with the sertraline (Rasgon et al. [@CR43]). Estrogen did not alter the final response rate to sertraline; however, the estrogen group improved more rapidly than the placebo group (data not shown).

Discussion {#Sec6}
==========

To further understand the role of neuroactive steroids in postmenopausal depression and mechanism of action of estrogen and SSRIs in this disorder, we compared the concentrations of serum ALLO, THDOC, DHEA and the neuroactive precursor PROG between postmenopausal women with depression and asymptomatic postmenopausal controls. Neuroactive steroids were studied before and after the administration of sertraline with the addition of estrogen or placebo in the depressed group, and estrogen or placebo (no SSRI) in the group of asymptomatic postmenopausal women, as part of a larger double blind, placebo controlled study of estrogen augmentation of SSRIs in post menopausal women with depression (Rasgon et al. [@CR43]). The major finding of this current study was significantly lower baseline DHEA and ALLO in postmenopausal women with major depressive disorder compared with healthy controls. In the depressed women, exposure to sertraline failed to affect NAS concentrations. Estrogen administration did not significantly alter NAS levels in either the depressed or control subjects.

Our study supports previously published reports of lower baseline levels of DHEA or DHEA in its sulfated form (DHEAS) in depressed populations compared to controls (Barbaccia et al [@CR1]; Yaffe et al. [@CR66]; Barrett-Connor et al. [@CR2]; Michael et al. [@CR28]; Berr et al. [@CR6]). However, the literature on DHEA and depression is inconsistent with publications also reporting higher levels (Tollefson et al. [@CR57]; Osran et al. [@CR35]; Heuser et al. [@CR19]; Takebayashi et al. [@CR56]), or no differences (Fabian et al. [@CR14]; Erdincler et al. [@CR13]; Romeo et al. [@CR44]). The discrepancy in DHEA results may be explained in part by differences in the age, gender or health of the subjects (Van Broekhoven and Verkes [@CR62]). DHEA clearly declines with age and debility (Orentreich et al. [@CR34]) but our depressed subjects and controls were comparable in age and were all healthy except for the diagnosis of depression. Yaffe et al. ([@CR66]) and Barrett-Connor et al. ([@CR2]) sampled large numbers (*n* = 699 and 394 respectively) of community dwelling postmenopausal women, and both studies also found DHEAs or DHEA to be non detectable or lower in postmenopausal women with depressive symptoms compared to postmenopausal controls. Barbaccia et al. ([@CR1]) had similar findings in a sample of 25 postmenopausal depressed women. Morrison et al. ([@CR32]) found that lower levels of DHEAs were correlated with higher depressive scores in the older half of the sample (older than 41 years versus younger than 41 years); by contrast, in the younger half of the sample, higher DHEA levels correlated with higher depressive scores. The hypothalamic-pituitary-adrenal (HPA) axis stress response may differ in older compared to younger depressed patients.

Lower plasma DHEA/S has also been associated with higher levels of stress and with trait anxiety (Diamond et al. [@CR12]). We did not find a correlation of NAS with anxiety in our subjects. The role of DHEA in regulating mood remains unknown. DHEAs are negative allosteric modulators of the GABA~A~ receptor (Majewska [@CR25]) with paradoxical effects in depression and anxiety as DHEA supplementation has been reported to improve well being and depression in elderly subjects and to be anxiolytic (Wolkowitz et al. [@CR65]; Van Broekhoven and Verkes [@CR62]; Morales et al. [@CR29]; Yen et al. [@CR67]; Wolkowitz et al. [@CR64]).

The DHEA antidepressant action has been attributed, among other theories, to augmentation of serotonin and norepinepherine or to metabolism of DHEA to testosterone or estrogen (Van Broekhoven and Verkes [@CR62]; Morley et al. [@CR31]). As we previously reported, estrogen did accelerate the antidepressant response compared with SSRI treatment alone. We did not however see a change in DHEA concentrations post treatment, which adds to the inconsistent findings of effect of pharmacologic therapy on DHEA levels (Van Broekhoven and Verkes [@CR62]).

Our results also support previous reports of lower ALLO in depressed subjects compared to controls (Romeo et al. [@CR44]; Strohle et al. [@CR53]; Uzunova et al. [@CR58]). However, not all studies have confirmed this relationship. ALLO was found to be higher in depressed subjects than controls by others (Barbaccia et al. [@CR1]; Hardoy et al. [@CR18]). ALLO also produced antidepressive effects in the mouse forced swim test model of depression (Khisti and Chopde [@CR21]) and has been postulated to act via the HPA axis and on serotonin and norepinepherine neurotransmission (Van Broekhoven and Verkes [@CR62]). However these putative antidepressant effects after the administration of ALLO may not necessarily contribute to the efficacy of pharmacologic therapy. Contrary to the findings of others (Romeo et al. [@CR44]; Uzunova et al. [@CR58]; Strohle et al. [@CR54]), we failed to find an increase in ALLO or THDOC after treatment of depression with SSRIs, suggesting increases in plasma ALLO are not required for treatment response. Other studies utilizing partial sleep deprivation or repetitive transcranial magnetic stimulation to treat depressed subjects also found NAS were not affected by either intervention regardless of response status (Schule et al. [@CR49]; Padberg et al. [@CR36]). This study adds to the body of the literature suggesting that a change in NAS is not essential for successful treatment of depression (with or without pharmacological interventions), or it is possible that the NAS response may occur at later, not initial, stage of antidepressant treatment.

Similarly, we did not find an increase in NAS after estrogen supplementation. Others have found increased ALLO and DHEA in non-depressed postmenopausal women given various regimens of hormone therapy (estrogen, estrogen/progestin, or tibolone), but the studies were not controlled for placebo effect (Bernardi et al. [@CR4]; Pluchino et al. [@CR41]). Additionally, our subjects lacked menopausal symptoms and the increase in NAS found by others could relate to improvement in menopausal symptoms. We also studied a small group of subjects and further studies with larger numbers will be important.

There is considerably less literature on THDOC and depression in clinical populations. Baseline THDOC levels were found to be higher in depressed subjects compared to controls (Strohle et al. [@CR53]; Strohle et al. [@CR54]). Similar to others (Rupprecht and Holsboer [@CR47]; Hardoy et al. [@CR18]), we detected no differences in THDOC in depressed subjects compared to controls. However, the high standard deviation may also account for failure of significance.

A consensus is forming from preclinical and clinical research indicating that neuroactive steroids are involved in the pathophysiology of depression and possibly response to treatment. However, a direct correlation with NAS and diagnosis or outcome has not been definitively established in humans. The specificity of the NAS assays can also lead to discrepancies; gas chromatography, mass spectrometry, or high performance liquid chromatography and radioimmunoassays may give different levels of NASs (Pearson Murphy and Allison [@CR38]). Furthermore, the results of this study are limited by the small sample size and the fact that we were unable to compare the effects of sertraline and estrogen on NAS in the early versus late post menopausal state. Further research including central nervous system NAS investigation is also needed.
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